A new drug design targeting the adenosinergic system for Huntington's disease.
2011
Background
Huntington's disease (HD) is a neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. The expanded CAG repeats are translated into polyglutamine (polyQ), causing aberrant functions as well as aggregate formation of mutant Htt. Effective treatments for HD are yet to be developed.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
96
References
66
Citations
NaN
KQI